I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| epithelial cell | 3 studies | 19% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell | 3 studies | 19% ± 3% |
Insufficient scRNA-seq data for expression of CES3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 4346.58 | 226 / 226 | 81% | 17.43 | 329 / 406 |
| kidney | 98% | 1394.19 | 87 / 89 | 66% | 27.72 | 599 / 901 |
| intestine | 65% | 3697.42 | 629 / 966 | 83% | 21.65 | 440 / 527 |
| pancreas | 99% | 428.81 | 325 / 328 | 41% | 4.08 | 73 / 178 |
| stomach | 34% | 150.90 | 122 / 359 | 75% | 14.84 | 214 / 286 |
| ovary | 46% | 89.01 | 83 / 180 | 57% | 5.26 | 246 / 430 |
| muscle | 100% | 2605.66 | 803 / 803 | 0% | 0 | 0 / 0 |
| brain | 87% | 285.32 | 2294 / 2642 | 13% | 0.66 | 92 / 705 |
| breast | 62% | 213.88 | 285 / 459 | 27% | 3.18 | 297 / 1118 |
| esophagus | 42% | 245.98 | 605 / 1445 | 46% | 6.95 | 85 / 183 |
| lung | 33% | 61.38 | 193 / 578 | 42% | 4.69 | 481 / 1155 |
| skin | 61% | 134.31 | 1103 / 1809 | 11% | 1.08 | 54 / 472 |
| thymus | 47% | 67.62 | 304 / 653 | 9% | 0.54 | 55 / 605 |
| adipose | 53% | 108.26 | 634 / 1204 | 0% | 0 | 0 / 0 |
| prostate | 35% | 70.56 | 85 / 245 | 9% | 1.18 | 44 / 502 |
| adrenal gland | 24% | 34.57 | 61 / 258 | 19% | 1.66 | 44 / 230 |
| uterus | 12% | 31.33 | 20 / 170 | 27% | 2.99 | 123 / 459 |
| bladder | 0% | 0 | 0 / 21 | 34% | 6.59 | 173 / 504 |
| lymph node | 0% | 0 | 0 / 0 | 31% | 2.21 | 9 / 29 |
| heart | 30% | 43.93 | 255 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 29% | 2.01 | 13 / 45 |
| peripheral blood | 18% | 53.40 | 169 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 7% | 10.53 | 94 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 6% | 10.33 | 15 / 241 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 5% | 0.22 | 4 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006805 | Biological process | xenobiotic metabolic process |
| GO_0034383 | Biological process | low-density lipoprotein particle clearance |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005829 | Cellular component | cytosol |
| GO_0106435 | Molecular function | carboxylesterase activity |
| GO_0052689 | Molecular function | carboxylic ester hydrolase activity |
| Gene name | CES3 |
| Protein name | Carboxylic ester hydrolase (EC 3.1.1.-) Carboxylesterase 3 (EC 3.1.1.1) (Liver carboxylesterase 31 homolog) Carboxylesterase 3 |
| Synonyms | FLJ21736 UNQ869/PRO1887 hCG_1775398 |
| Description | FUNCTION: Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows low catalytic efficiency for hydrolysis of CPT-11 (7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin), a prodrug for camptothecin used in cancer therapeutics. |
| Accessions | A0A0C4DFY7 H3BUA3 ENST00000394037.5 ENST00000566453.1 ENST00000570236.1 ENST00000303334.9 [Q6UWW8-1] H3BRE5 ENST00000543856.1 [Q6UWW8-2] Q6UWW8 |
